Short Title: EYS is a major gene for arRP Communicated by <Please don't enter> ABSTRACT: Autosomal-recessive retinitis pigmentosa (arRP) was recently associated with mutations in a novel gene EYS, spanning over 2 Mb, making it the largest known gene expressed in the human eye. The purpose of this study was to establish the prevalence and nature of EYS mutations in a clinically well-characterized cohort of 239 sporadic and arRP French cases. Direct sequencing of EYS was performed in 186 subjects for whom known mutations had previously been excluded by applying microarray technology. We mostly identified novel mutations in EYS in a total of 29 patients: Fifteen of the mutations were predicted to create premature stop codons and two represent exonic deletions. In addition, twenty missense, silent or splice-site mutations were detected. Patients revealed homozygous or compound heterozygous mutations and in some cases, only a single mutation. Most patients showed classical signs of RP with relatively preserved central vision and visual field until late in the course of the disorder. One patient showed predominance of the disease in the inferior part of the retina suggesting potential phenotypic variability. With a prevalence of 12% or more we provide evidence that EYS is a major gene for RP in France and probably elsewhere. ©2010 Wiley-Liss, Inc. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w INTRODUCTION Rod-cone dystrophy also known as Retinitis Pigmentosa (RP) is a heterogeneous group of inherited disorders primarily affecting rods with secondary cone degeneration. It is the most common inherited form of potentially severe retinal degeneration and blindness, with a frequency of about 1 in 4000 births and more than 1 million individuals affected worldwide. (Hartong et al. 2006) . Patients initially complain of night blindness due to rod dysfunction followed by progressive visual field constriction, abnormal colour vision and eventually loss of central vision. Inheritance of RP can be either autosomal recessive (ar), autosomal dominant (ad) or X chromosomal (xl) with also rare cases of mitochondrial transmission. Recessive and isolated cases account for 50-60% of all forms of RP. (Hartong et al. 2006 ). So far, 26 genes have been implicated in arRP and 4 additional loci have been mapped (http://www.sph.uth.tmc.edu/Retnet). Until recently, most of the identified genes accounted for only 1-2% of cases each, besides USH2A (OMIM:608400) which was found to be mutated in more than 5% of arRP without hearing loss (Rivolta et al. 2000; Bernal et al. 2003) . Linkage analysis, initially performed in Spanish families (Ruiz et al. 1998) , mapped the RP25 locus on chromosome 6q, which was subsequently reproduced in families from Pakistani (Khaliq et al. 1999) and Chinese origins (Abd El-Aziz et al. 2007 ). Additional Spanish families were also mapped to the same locus (Barragan et al. 2008) . The high frequency of linkage to RP25 found in the Spanish population (13.7 to 27.7%) and the reproduction of this linkage in families from other parts of the world, suggested RP25 to be a major locus for arRP (Barragan et al. 2008) . Refinement of the genetic interval followed by a bioinformatics based systematic positional cloning approach led to the identification of EYS (NCBI Reference Sequence: NM_001142800.1, OMIM: 612424) as the gene responsible for RP25 (Abd El-Aziz et al. 2008; Barragan et al. 2008) . Authors reported 6 different mutations in 5 unrelated Spanish families including 4 deletions and 2 nonsense substitutions. All these changes were predicted to result in a premature stop codon leading to nonsense-mediated decay of the resulting mRNA with complete absence of a functional protein (Abd El-Aziz et al. 2008) . Independently, Collin and co-workers, using homozygosity mapping, reported 3 consanguineous families linked to the RP25 locus with 2 of them showing the same frameshift mutation in EYS indicative of a founder effect and one with a homozygous nonsense mutation, both changes predicted to result in a premature termination codon and protein truncation (Collin et al. 2008) . Abd El -Aziz and co-workers described EYS as a large gene spanning approximately 2Mb of genomic DNA. The gene contains 43 exons, of which exons 4-43 encode a protein with 3144 amino acids (Abd El-Aziz et al. 2008) . The study by Collin and co-workers revealed a similar gene structure with an additional exon between exon 41 and 42, making the predicted protein slightly larger with a size of 3165 amino acids (Collin et al. 2008) . Both groups reported EYS as the human ortholog of the Drosophila 'eyes shut' (eys) gene, also known as spacemaker or spam, which plays an important role in photoreceptor morphogenesis in the insect eye with an open system such as in fruitflies and houseflies (Zelhof et al. 2006) . The predicted human SPAM/EYS protein, consists of multiple epidermal growth factor (EGF)-like domains in its N-terminus followed by several Laminin G-like domains, interspersed by further EGF-like repeats, at the C-terminus (Abd El-Aziz et al. 2008) . It was shown to be specifically expressed in the human retina and Y79 retinoblastoma cell lines, with a subcellular localization in the photoreceptor outer segment in porcine retina (Abd El-Aziz et al. 2008; Collin et al. 2008) . The additional exon identified by Collins and co-workers belongs to a retina-specific alternative spliced variant, which can be present or not (Collin et al. 2008) . Based on the known function of the drosophila ortholog, EYS is expected to play an important role in retinal morphogenesis and maintenance of its integrity. To investigate if EYS mutations are a major cause for RP in autosomal recessive and simplex cases, we evaluated a French cohort comprising 239 individuals including patients of different ethnic origins.
PATIENTS AND MATERIALS
Two hundred and thirty nine index patients with a presumed diagnosis of simplex or arRP were ascertained. Informed consent was obtained from each patient and normal individual controls after explanation of the study and its potential outcome. The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the local ethics committee. Each patient underwent full ophthalmic examination with assessment of best corrected 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w < EYS is a major gene for arRP > 3 visual acuity, using the EDTRS chart, kinetic and static perimetry and colour vision using the desaturated Farnsworth Panel D-15. Full-field and multifocal electroretinography (ERG and mfERG) were performed with DTL recording electrodes and incorporated the ISCEV Standards (Espion² Diagnosys® for full field ERG and Veris II for Multifocal ERG) (Marmor et al. 2003; Marmor et al. 2004) . Clinical assessment was completed with Fundus Autofluorescence Imaging (FAF) and Optical Coherence Tomography (OCT) (HRAII® and Spectralis® OCT, Heidelberg Engineering, Dossenheim, Germany). At the end of clinical evaluation, patients and family members were asked to donate blood samples for further genetic studies. Total genomic DNA was extracted from peripheral blood leucocytes blood samples according to manufacturer recommendation (Puregen Kit, Qiagen, Courtaboeuf, France). Prior to EYS mutation analysis, the DNA of all index patients was analyzed for known mutations by microarray analysis on a commercially chip (ASPER Ophthalmics, Tartu, Estonia). In total the DNA of 186 index patients were excluded for a likely disease causing mutation by this approach and were further investigated for mutations in the coding exons and flanking intronic regions of EYS by PCR. The reaction mix contained 1.5 mM (2.5mM for exon 16) MgCl 2 and a commercially available polymerase (HOT FIREPol DNA Polymerase, Solis BioDyne, Tartu, Estonia) at an annealing temperature of 60°C using primers previously described (Abd El-Aziz et al. 2008) . PCR products were enzymatically purified (ExoSAP-IT, USB Corporation, Cleveland, Ohio, USA purchased from GE Healthcare, Orsay, France) and sequenced with a commercially available sequencing mix (BigDyeTerm v1.1 CycleSeq kit, Applied Biosystems, Courtaboeuf, France). For exon 12, two additional sequencing primers were used (EYS_Ex12seqF: 5'-GACTATTGCTTAGGGAACCAC-3' and EYS_Ex12seqR 5'-TCCTGGGACACACTTGCG-3'). The sequenced products were purified on a presoaked Sephadex G-50 (GE Healthcare) 96-well multiscreen filter plate (Millipore, Molsheim, France), the purified product analyzed on an automated 48-capillary sequencer (ABI 3730 Genetic analyzer, Applied Biosystems) and the results interpreted by applying a software (SeqScape, Applied Biosystems). Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.
Seven synthetic MLPA (Multiplex Ligation dependent Probe Amplification) probes for several exons of EYS including exons 12, 32 and 33 of EYS were designed according to the MRC Holland guidelines. Each probe sequence was checked for localization and putative polymorphisms using SNP databases (http://www.ncbi.nlm.nih.gov./, and http://genome.ucsc.edu/cgi-bin/hgBlat). A set of control probes was included in each synthetic probe mix in order to provide constant values. The reactions were carried out as previously described (Schouten et al. 2002) . The MLPA interpretation and analysis criteria were as follows: i) normal if the individual dosage quotient values were within a range of 0.8-1.0; ii) deletions or duplications if the dosage quotient values were around 0.5 or 1.5, respectively; and iii) the mean standard deviation of all samples for each peak should be below 10%.
RESULTS AND DISCUSSION
Prior to the mutation screening of EYS, the DNA of all index patients was analyzed for known mutations using a commercially available microarray chip (ASPER Ophthalmics, Tartu, Estonia) In total DNA samples from 186 index patients were excluded for a likely disease causing mutation using this approach. Mutation screening of EYS by direct sequencing of all coding exons revealed for 29 of the 186 patients one or two likely pathogenic nonsense, frameshift, missense, splice-site or silent mutations, which co-segregated with the phenotype when tested in family members available (Tables 1, 2 and 3). A sequence variant was considered to be pathogenic if the same nucleotide exchange was not found in another species, or if it represents a nonsense or frameshift mutation, or affects a conserved amino acid residue, which may localize in a predicted important domain of EYS, appeared only 1-3 times in 186 patients and did not appear in control samples investigated (total number of alleles studied ≥ 400, see Table 1 and 2). Furthermore, splice site (http://www.fruitfly.org/seq_tools/splice.html) and exonic splicing enhancer prediction programs (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) were applied to estimate the pathogenic nature of a sequence variant.
In total 12 of the 186 patients screened for EYS revealed 15 different new mutations, which are predicted to result in a truncated protein or lead to nonsense mediated mRNA decay ( Table 4 reported here versus Spanish published by Abd El-Aziz 2008), we hypothesize that this exonic deletion most probably represents a recurrent mutation rather than a founder effect in EYS. Furthermore, we report 14 likely pathogenic missense mutations in exons 12, 14, 22, 23, 25, 26, 29, 31, 32 and 43 (Tables 1 and 2 ). They either affect evolutionary well or highly conserved nucleotide and amino acid residues (Figure 1) or may have an effect on predicted functional regions of EYS like Laminin G, EGF/EGF-like or EGF/Laminin domains (Table 1) . Additionally, 4 putative pathogenic mutations at or close to splice sites in 4 different patients were identified (Tables 1 and 2 ).
1. The c.748+6A>T mutation in intron 4 identified in 1 patient affects a nucleotide, which is present in all but one case as an A (Figure 2 ). The pathogenicity of this exchange remains unclear since splicing was not predicted to be significantly changed compared to the normal sequence. 2. The c.2023+1G>C mutation in intron 12 identified in 1 patient affects a donor site, which is evolutionary and functionally highly conserved ( Figure 2 ) and may thus lead to exon skipping of exon 12: 3. The c.2847-1G>T mutation in intron 18 identified in 1 patient affects a predicted acceptor splice site, which is evolutionary and functionally conserved ( Figure 2 ) and is predicted to lead to skipping of exon 19. 4. Another mutation, c.3164+15insT in intron 20 detected in 1 patient might influence the regulation of EYS. However further functional tests are pending to prove this hypothesis. Also two putative pathogenic silent mutations were identified:
1. The c.5604A>T (p.Ser1868Ser) mutation in exon 26 detected in 1 patient affects a highly conserved nucleotide ( Figure 2 ). Two additional exon splicing enhancer proteins were predicted to bind to the sequence variant and might thus influence splicing (data not shown). 2. The c. 5886T>C (p.Thr1962Thr) mutation in exon 28 detected in 1 patient affects a conserved nucleotide.
Only in two species an A and G occurs instead of the T (Figure 2 ). Furthermore the mutation is predicted to delete a binding site for an exon splicing enhancerprotein (data not shown).
Thus our study revealed 29 patients with 15 nonsense mutations, 2 exonic deletions, 14 missense mutations, 4 splice site and 2 silent mutations, all predicted to be disease causing. In the two original articles describing the gene identification of EYS, frameshift and nonsense mutations were identified in exons 12, 15-19, 17, 28, 33, 41 and 43 . Together with our findings describing the prevalence in a large RP cohort, exons 4, 11, 12, 14, 15-19, 17, 20, 22, 23, 25, 26, 27, 28, 29, 31, 32, 33, 34, 41 and 43 harbor a likely pathogenic mutation and these exons might represent a common target for other cohort studies. However, all mutations identified in this study were novel and thus it is likely that other studies will find other exons of EYS to be frequently mutated in RP patients.
Of the 29 patients with a mutation in EYS, 13 were apparently homozygous or compound heterozygous for the mutations, while for the remaining patients the second mutation could not be identified (Table 2 ). This may be due to relatively large heterozygous deletions, which are not detectable by direct sequencing methods. When the DNA of proband's family members were available, we performed co-segregation studies which are summarized in Table  2 . See below some examples of such investigations in families reported here:
1. Patient CIC00513 (II-5) was apparently homozygous for a deletion, which is predicted to lead to a protein missing almost all predicted Laminin G domains (p.Lys1945SerfsX42). The mutation co-segregated with the phenotype: The mother (I-2) and the two unaffected sisters (II-1 and II2) were heterozygous and the affected brother (II-3) homozygous for the mutation ( Figure 3 , Fam 347). 2. Interestingly patient CIC00951 (II-3) and his affected brother CIC03294 (II-1) carried 3 nonsense mutations: two in exon 26 (p.Gln1751X and p.Tyr1753X) and one in exon 43 (p.Tyr3059X). Co-segregation analysis revealed that the mother (I-2) carried the p.Gln1751X and p.Tyr3059X on the same allele, while the father (I-1) carried the p.Tyr1753X mutation (Figure 3, Fam 602) . Since the affected brother showed the same genotype as the index patient it is not possible to say which of the two changes inherited from the mother may < EYS is a major gene for arRP > 5 be pathogenic. However, if all mutations in this family would lead to a premature stop codon or nonsense mediated mRNA decay, it is then likely that all three mutations can be disease causing. 3. Index patient CIC01265 (II-1) was compound heterozygous for two different alterations (one deletion and one insertion), both predicted to lead to a truncated protein (p.Thr308IlefsX4 and Asn3123LysfsX4), which co-segregated with the disease. The affected sister also showed both mutations, the father was heterozygous for the p.Thr308IlefsX4, while the mother carried the other Asn3123LysfsX4 mutation ( Figure 3 , Fam 760). Thus, although we could show for some families co-segregation of the mutations with the phenotype and our criteria to classify a mutation as pathogenic was quite stringent, functional analysis of the mutations are needed to further prove the pathogenic character of these changes.
Genotype-Phenotypic characterization
Clinical and functional findings are summarized in table 4 and table 5, respectively. Patients' age ranges from 3 to 58 years at the time of diagnosis, with an average age of 25 years and from 16 to 73 at time of testing with an average age of 39 years. The patients came from diverse geographical origins including Europe, North Africa, West Africa and Egypt. They show typical signs of progressive rod-cone dystrophy with relatively preserved central vision and visual field until late in the course of the disorder, except for 2 patients (CIC01223 and CIC00492), for whom loss of central vision appeared early in the course of the disease. For most patients, symptoms include early onset night blindness, followed by progressive visual field constriction and a certain degree of photophobia later in the course of the disease. Three patients did not report night blindness at onset but instead one reported photophobia (CIC00167) and two others reported constricted visual fields at time of diagnosis (CIC00139 and CIC01066). Strabismus was present in 2/29 patients (CIC00081 and CIC00656). All patients were ametropic except one showing various degree of myopia, hyperopia or astigmatism. Regarding visual acuity, only two patients, aged 30 and 48 years, show vision limited to hand motion perception and this low vision is associated with atrophic changes within the macula. The other patients have 20/100 vision or better at least in one eye and, when measurable, Best Corrected Visual Acuity (BCVA) ranges between 20/16 and 20/100 and tend to be worse in older patients. Anterior segment examination show small pigmented opacities on posterior capsule for one 19 year-old patient. Ten other patients, age 34 and older had subcapsular cataract or had undergone cataract surgery. Fundus examination shows typical sign of RP for most patients with pale optic nerve disc, narrowed blood vessels, pigment changes with intraretinal migration over 360° of the fundus (Figure 4 , patient CIC00656), which are more prominent in older patients. Two patients show small white dots in the peripheral retina with limited pigment migration. No white dots were visible when RPE changes and pigment migration were prominent. Two patients had more severe involvement with retinal atrophy involving the posterior pole (Figure 4 , CIC00656). One patient (CIC01222) showed distinct fundus abnormalities with predominance of pigmentary changes in the inferior part of both retinas resembling sector RP (Figure 4, patient CIC01222 ). This represents a distinct phenotype, which is usually associated with autosomal dominant RP linked to mutations in the rhodopsin gene (RHO, OMIM: 180380) (Heckenlively et al. 1991) (Audo et al. 2010 ). However, ERG responses (Table 5) were not detectable for this patient, consistent with severe generalized rod-cone dysfunction which is unusual for typical sector RP associated with rhodopsin mutation. The role of light exposure is usually suggested to explain the preferred location of retinal involvement. Since the precise function of EYS in photoreceptor biology is unknown, there is no accurate explanation for mutations leading to this peculiar sectorial phenotype and it can be speculated that EYS may be interacting or influencing rhodopsin expression. In addition, one patient had a history of Coats disease treated by cryo-application, a feature often associated with mutations in the CRB1 gene (OMIM: 604210) (den Hollander et al. 2001) . Twelve patients showed macular atrophic changes. Nine patients had a history of cystoid macular edema (CMO) (31%) which is consistent with previous reports on CMO frequency in RP (Hajali et al. 2008 ). The two later macular changes were confirmed with Optic Coherence Tomography. On Fundus Autofluorescence imaging, 14/29 patients showed a perifoveal ring of increased autofluorescence (Figure 4 , patients CIC00589 and CIC01265) and its absence was correlated with the presence of atrophic changes and loss of autofluorescence within the macula (Figure 4 , patient CIC00656). Tritanopia was the most common color abnormality in this cohort: color vision was normal in 6/29 patients, showed a dyschormatopsia with tritan axis in 16/29 patients in at least one eye, a dyschromatopsia with no major axis in 8/29 and could not be tested due to low vision in 2/29 patient. There was a correlation between the presence of a dyschromatopsia and visual acuity or between the presence of a dyschromatopsia and atrophic changes within the macula. Overall, in 12% of this French cohort with autosomal recessive or simplex RP we have identified at least one very likely pathogenic mutation providing evidence that EYS is a major gene for RP in France and probably elsewhere. Most patients showed classical signs of RP with relatively preserved central vision and visual field until late in the course of the disease. One patient with predominance of the disease in the inferior part of the retina would suggest potential phenotypic variability, a hypothesis which needs to be confirmed from studies analyzing other cohorts.
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